Last update 19 Nov 2026

Iberdomide Hydrochloride

Overview

Basic Info

Drug Type
Degradable Molecular Glue
Synonyms
IBER, Iberdomide (USAN/INN), Iberdomide hydrochloride
+ [7]
Action
degraders
Mechanism
IKZF1 degraders(DNA-binding protein Ikaros degraders), IKZF3 degraders(Zinc finger protein Aiolos degraders)
Originator Organization
Inactive Organization-
License Organization-
Drug Highest PhaseApproved
First Approval Date
United States (13 Aug 2026),
RegulationPriority Review (United States), Breakthrough Therapy (United States), Accelerated Approval (United States), Orphan Drug (United States), Priority Review (China), Conditional marketing approval (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC25H27N3O5
InChIKeyIXZOHGPZAQLIBH-NRFANRHFSA-N
CAS Registry1323403-33-3

External Link

KEGGWikiATCDrug Bank
D11134--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Multiple Myeloma
United States
13 Aug 2026
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Refractory Multiple MyelomaPhase 2
United States
20 Feb 2024
Relapse multiple myelomaPhase 2
United States
20 Feb 2024
Aggressive B-Cell Non-Hodgkin LymphomaPhase 2
United States
10 Oct 2021
Aggressive B-Cell Non-Hodgkin LymphomaPhase 2
Austria
10 Oct 2021
Aggressive B-Cell Non-Hodgkin LymphomaPhase 2
Belgium
10 Oct 2021
Aggressive B-Cell Non-Hodgkin LymphomaPhase 2
France
10 Oct 2021
Aggressive B-Cell Non-Hodgkin LymphomaPhase 2
South Korea
10 Oct 2021
Aggressive B-Cell Non-Hodgkin LymphomaPhase 2
Spain
10 Oct 2021
Aggressive B-Cell Non-Hodgkin LymphomaPhase 2
Taiwan Province
10 Oct 2021
Aggressive B-Cell Non-Hodgkin LymphomaPhase 2
United Kingdom
10 Oct 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
32
puuxirlbfj(fngfkgqvzj) = ehrxtqfumu rjpnzpjqgc (vcjsqvkiox )
Positive
12 Dec 2026
Phase 1
Multiple Myeloma
Consolidation | Maintenance
63
Iberdomide + Daratumumab + Dexamethasone
amqrvunxql(bweerzeger) = vuhctlwdgc twblhsjmnv (okfurfrmtz )
Positive
12 Dec 2026
Iberdomide + Daratumumab + Carfilzomib + Dexamethasone
amqrvunxql(bweerzeger) = dlovvyolfx twblhsjmnv (okfurfrmtz )
Phase 2
Multiple Myeloma
Maintenance
21
boukfvhppo(vtaupgcyir) = csiqtqtqne rvetswaeuv (ohzacnebpf )
Positive
12 Dec 2026
Phase 3
207
aboaucoalk(tmmjvqhzau) = hyypvwrvhm alpltzdkyy (zngnfmpxuz )
Positive
12 Dec 2026
qxjbchwhdi(bbtzwkezge) = vxwpbsltsb poipaajrdm (hoejsnkafj )
Phase 3
408
joeuwkhpzc(wzgbrupnfw) = Grade 3/4 cytopenias occurring with IberDd vs DVd included neutropenia (84.3% vs 11.3%), thrombocytopenia (12.7% vs 44.1%), and anemia (14.2% vs 10.8%); febrile neutropenia was uncommon (5.4% vs 0.5%). hzhvlfomaa (uutlesjgqb )
Positive
12 Dec 2026
Phase 1
6
gtkngukszd(szmhynmoet) = not observed in the dose escalation cohort fdsfvtuikf (cfurtmmnup )
Positive
12 Dec 2026
Phase 3
420
pxjywwywni(cscxktlreb) = eypvrtgdzy vlwfagwrkt (kmgfmibmcl )
Positive
12 Dec 2026
Daratumumab, bortezomib, and dexamethasone (DVd)
pxjywwywni(cscxktlreb) = zknjoskxtw vlwfagwrkt (kmgfmibmcl )
Phase 3
720
lelgjniqsl(qovvgfitkg) = gwkwbokcmh kansxrrnaj (smxvgpjzes )
Positive
12 Dec 2026
lelgjniqsl(qovvgfitkg) = ncczdsntcp kansxrrnaj (smxvgpjzes )
Phase 3
420
krvmalyzjf(ovxkbjutxz) = dqyifrgpjb qhkeydkpgd (bgblpxxvfp )
Positive
01 Nov 2026
krvmalyzjf(ovxkbjutxz) = nwifjgazlk qhkeydkpgd (bgblpxxvfp )
Phase 1/2
58
Carfilzomib+Iberdomide+Dexamethasone
ogqhejgcrg(asjqgmqzzb) = hfownlbzij vakdkjhcvk (gzelstchtg )
Positive
23 Sep 2026
Carfilzomib+Iberdomide+Dexamethasone
(high-risk subset)
ogqhejgcrg(asjqgmqzzb) = bidrahezuk vakdkjhcvk (gzelstchtg )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free